Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.
Ahmet KarataşRabia Pişkin SağırSuleyman Serdar KocaHüseyin Ediz DalkılıçGercek SenPehlivan YavuzAyten YazıcıGüzide Nevsun İnançAyşe CefleZeynep ErtürkServet AkarAbdurrahman Soner ŞenelAhmet Merih BirlikNurullah AkkocFatoş ÖnenPublished in: Turkish journal of medical sciences (2023)
In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that obesity does not alter drug survival for rituximab and response rates, in RA and rituximab may be a favorable treatment agent in patients with RA and obesity.
Keyphrases
- diffuse large b cell lymphoma
- metabolic syndrome
- body mass index
- weight loss
- rheumatoid arthritis
- type diabetes
- insulin resistance
- chronic lymphocytic leukemia
- hodgkin lymphoma
- adipose tissue
- ankylosing spondylitis
- high fat diet induced
- emergency department
- physical activity
- skeletal muscle
- systemic lupus erythematosus
- replacement therapy
- obese patients